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RESUM
La placenta humana es caracteritza per la intensitat i especificitat de les seves funcions en-
docrines. La hormones de la placenta són necessàries per a l’establiment i manteniment de
l’embaràs, per a l’adaptació a aquest de l’organisme femení, per al creixement del fetus així i
per al desenvolupament dels mecanismes implicats en el part. El teixit endocrí de la placenta
és el sinciciotrofoblast, que cobreix les vellositats coriòniques o estructura principal d’intercan-
vi. La utilització de cultius primaris de citotrofoblasts ha proporcionat molta informació sobre
els mecanismes implicats en la formació del sinciciotrofoblast per fusió cèll. ula-cèll. ula. Immers
en la sang materna, el sinciciotrofoblast secreta la major part de les seves hormones polipep-
tídiques a la circulació materna. Entre d’altres, la gonadotrofina coriònica (hCG) fa una funció
essencial en el manteniment del cos luti i està directament implicada en la diferenciació del
trofoblast. L’hormona de creixement (GH) placentària està també secretada contínuament pel
sinciciotrofoblast i substitueix la GH hipofisària durant l’embaràs. Mitjançant la captura del co-
lesterol a partir de les lipoproteïnes maternes, el sinciciotrofoblast sintetitza una gran quantitat
de progesterona necessària per a l’estabilitat de l’úter. El sinciciotrofoblast, en no tenir l’enzim
citocrom P450 17 α-hidroxilasa/17-20-liasa, utilitza els andrògens adrenals materns i fetals per
a sintetizar estrògens. Com a conclusió, és important esmentar que en l’observació de qualse-
vol anomalia hormonal durant l’embaràs hauràn de tenir-se en compte aquestes dades i, en
particular, les característiques enzimàtiques de la placenta.Paraules clau: hormones de l’embaràs, trofoblast humà, sinciciotrofoblast, hCG, esteroido-
gènesi.
SUMMARY
The human placenta is characterized by the intensity and the specificity of its endocrine func-
tions. Placental hormones are required for the establishment and maintenance of pregnancy,
the adaptation of the maternal organism to pregnancy, fetal growth and well being, and the
development of the mechanisms involved in parturition. The endocrine tissue of the placenta
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is the syncytiotrophoblast, which covers the chorionic villi, the main structure of exchange.
Primary cultures of villous cytotrophoblasts have provided insight into the mechanisms in-
volved in syncytiotrophoblast formation by cell-cell fusion. Bathing in maternal blood, the syn-
cytiotrophoblast secretes the majority of its polypeptide hormones into maternal circulation.
Among those, hCG (human chorionic gonadotropin) plays an essential role in the maintenance
of the corpus luteum and is directly implicated in trophoblastic differentiation. The placental
GH (growth hormone) secreted continuously by the syncytiotrophoblast replaces the mater-
nal pituitary GH during pregnancy. Capturing the cholesterol from the maternal lipoproteins,
the syncytiotrophoblast synthesizes large amounts of progesterone essential for uterine qui-
escence. Deprived of cytochrome P450 17αhydroxylase/17-20lyase, it uses the maternal and
fetal adrenal androgens to synthesize estrogens. The observation of any maternal hormonal
anomaly during pregnancy must take into account these data and, in particular, the enzymatic
characteristics of the placenta.Keywords: pregnancy hormones, human trophoblast, syncytiotrophoblast, hCG, steroido-
genesis.
The human placenta is a villous placenta;
the structural and functional unit of the hu-
man placenta is the chorionic villous, which
becomes apparent in its definitive structure as
early as day 21 of pregnancy (Loke and King,
1993; Bernischke and Kaufmann, 2000) (see
figure 1).
After nidation, the trophoblast differenti-
ates into two forms: the villous and the extra-
villous trophoblast. In the villous phenotype,
the cytotrophoblastic cells of the floating villi
(in the intervillous space) remain attached to
the villous basement membrane, forming a
monolayer of epithelial cells. These cells pro-
liferate and differentiate by fusion to form a
syncytiotrophoblast that covers the entire sur-
face of the villus (see figure 1). This membrane
fusion process is complex and involves differ-
ent factors. The so-called “phosphatidylserine
flip” (Adler et al., 1995) associated with cas-
pase 8 activity (the caspase initiator) (Hup-
pertz et al., 2001) has been implicated. The
requirement of an endogenous retroviral en-
velope protein (Blond et al., 2000; Mi et al.,
2000; Frendo et al. 2003a), connexin 43 (Frendo
et al., 2003b; Cronier et al., 2003) and cadherin
11 (Getsios and MacCalman, 2003), has been
demonstrated. In the extra-villous phenotype,
the cytotrophoblastic cells of the anchoring
villi, in contact with the uterine wall, prolifer-
ate, detaching from the basement membrane
and aggregating into multilayered columns
of non-polarized cells that rapidly invade the
uterine wall. This trophoblastic invasion is
confined to the endometrium, the first third
of the myometrium, and the associated spi-
ral arterioles. This invasion process is asso-
ciated with the complete remodeling of the
spiral artery wall, leading to the disappear-
ance of the muscle layer and the replacement
of endothelial cells by trophoblasts (endovas-
cular trophoblasts) (Pijnenborg et al., 1981).
This trophoblastic endovascular invasion is of
major importance to the feto-placental phys-
iology: intra-arterial plugs of endovascular
trophoblasts prevent, until the twelfth week
of gestation, the access of maternal blood
to the intervillous space and, therefore, protect
the conceptus from excessively high oxygen
levels during this very critical stage of de-
velopment (Burton et al., 1999; Hustin et al.,
1990; Hustin and Schapps, 1987). In addition,
an abnormally deficient arterial remodeling is
involved in pre-eclampsia, a disorder that is
specific to human pregnancy and manifests it-
self during the second trimester of pregnancy,
with maternal hypertension and proteinuria
(see for review Sibai et al., 2005).
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The syncytiotrophoblast is multifunctional,
but its primary functions are absorption, ex-
changes, and hormonal production. The syn-
cytiotrophoblast is strongly polarized and
secretes the majority of its polypeptide hor-
mones into maternal circulation (Linnemann
et al., 2000). The syncytiotrophoblast, which
has the same chromosomal pattern as the fe-
tus, is a female or male endocrine factory.
The syncytiotrophoblastic mass appears to
be more important in female placentas. This
could explain the slightly higher hormone
levels of syncytiotrophoblastic origin found
in maternal circulation in the event of a fe-
male fetus (Chellakooty et al., 2004). It should,
however, be noted that the differences in the
hCG levels in maternal serum, according to
fetal sex, are not sufficient to interfere with
the screening of fetal trisomy 21 by maternal
serum markers. Studies of primary cultures
have provided insight into human villous tro-
phoblastic differentiation. Isolated villous cy-
totrophoblasts from early and term placen-
tas adhered to plastic dishes, aggregated and
fused together to form a non-proliferative,
multi-nucleated syncytiotrophoblast produc-
ing specific hormones (Kliman et al., 1986;
Alsat et al., 1991; Tarrade et al., 2001a). This
model can be used for studies of cell-cell fu-
sion, the regulation of hormone production,
and trophoblastic differentiation . It has also
been used to explore the genetic control of vil-
lous trophoblastic development, using a sub-
tractive cDNA library (Morrish et al., 1996)
and microarray technology (Aronow et al.,
2001; Handwerger and Aronow 2003) and by
proteomic analysis (Hoang et al., 2001). It has
also made it possible to identify a certain num-
ber of genes, such as those involved in coding
for the retinoid receptors and the activators of
the peroxisomes (PPARγ), which are directly
implicated in the formation and the differenti-
ation of the syncytiotrophoblast (Handwerger
et al., 2003; Tarrade et al., 2001b, c)
PLACENTAL POLYPEPTIDE
HORMONES
The syncytiotrophoblast secretes many
polypeptide hormones. They are primarily:
hCG (human chorionic gonadotropin) (see for
review: Jameson and Hollenberg, 1993), hPL
(human placental lactogen), or hCS (human
somatomammotropic hormone) and placental
GH (growth hormone) (see for review: Alsat
et al., 1997; Lacroix et al., 2002). The glyco-
protein hormone hCG is the key hormone of
human pregnancy. It behaves like a super-ag-
onist of LH, allowing the transformation of
cyclic ovary corpus luteum in gravidic corpus
luteum, ensuring the maintenance of ovar-
ian progesterone secretion during the first 6
weeks of pregnancy (Jameson and Hollen-
berg, 1993; Srisuparp et al., 2001; Maston and
Ruvolo, 2002). After six weeks of pregnancy,
the steroidogenic activity of the feto-placen-
tal unit compensates for the maternal ovar-
ian functions. Thus, an ovariectomy after 6
weeks of pregnancy has no effect on a preg-
nancy’s outcome. HCG is made up of two
subunits, an alpha sub-unit and a beta sub-
unit. The alpha subunit is the same in the
other glycoproteic hormones (FSH, LH, and
TSH). The alpha subunit is made up of 92
amino acids with two N-glycosylation sites.
It is encoded by only one gene on the chro-
mosome 6q21.1-23. The beta subunit is made
up of 145 amino acids with two sites of N-
glycosylation and 4 sites of O-glycosylation.
It is encoded by a whole set of genes, six
beta genes, a CG beta pseudogene and an LH
beta gene on the chromosome 19q13.3. These
CG beta genes evolve by duplication from
the LH beta gene and are controlled differ-
ently on the level of their promoter. Compared
to LH, the 31 additional amino acids in the C-
terminal position of hCG and hCG’s very high
glycosylation levels allow its intracellular traf-
ficking towards the apical membrane of the
syncytiotrophoblast, its secretion directly into
maternal circulation, and its prolonged half-
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Figure 1. Scheme of human chorionic villi.
life. (Jablonka-Shariff et al., 2002). By an au-
tocrine and paracrine mechanism, hCG plays
an essential role in trophoblastic differenti-
ation and stimulates in vitro the differentia-
tion of the cytotrophoblasts in the syncytiotro-
phoblast (Shi et al., 1993; Yang et al., 2003).
Recently hCG was characterized as a new an-
giogenic factor involved in the establishment
and the development of the human placenta
(Zygmunt et al., 2002). The human trophoblast
expresses two types of hCG receptor: a trun-
cated 50 kD isoform and an 80 kD full-length
isoform (Licht et al., 1993). The truncated iso-
form is expressed during the first trimester
of pregnancy, and the full-length isoform is
expressed in the highly-differentiated term
trophoblast. Other hCG receptors have been
identified in non-gonadal tissue and shown
to be involved in the normal course of preg-
nancy (Licht et al., 2001; Rao, 2001). To our
knowledge, no informative mutations affect-
ing hCG genes have been described, suggest-
ing that hCG is absolutely required for the
initiation of pregnancy. The secretion of hCG
by the trophoblast appears very early; it be-
gins as soon as the 7th day after fecundation at
the time of implantation. The concentrations
of maternal hCG increase gradually, reaching
a maximum peak by about the tenth week,
and then decrease very clearly during the 3rd
month to remain practically stationary until
childbirth. The reasons for this maternal plas-
matic peak of hCG during the first trimester
of pregnancy remain to be discussed. The
following hypotheses have been suggested:
1, at this stage of pregnancy the presence
of the truncated form of the receptor would
block the autocrine regulation of hCG synthe-
sis; 2, the synthesis of hCG by the trophoblast
varies during the pregnancy and is higher
during the first trimester; and, 3, hCG would
be controlled by an autocrine/paracrine
mechanism, by GnRH, produced by the cy-
totrophoblasts that are present in greater
numbers during the first trimester (see for re-
view: Malassiné et al., 2003). Several recent
studies have demonstrated the importance of
the glycosylation state of hCG, which varies
according to the stage of the pregnancy (Diaz-
Cueto et al., 1996). Choriocarcinoma cells
(Eliot et al., 1997) and trophoblast cells dis-
playing chromosome 21 trisomy (Frendo et al.,
2004) produce abnormally glycosylated forms
of hCG with low biological activity. It should
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be noted that no CG beta genes have been
found in mice (Maston and Ruvolo, 2002).
It has been known for many years that
the syncytiotrophoblast secretes very large
amounts of hCS or hPL into the maternal com-
partment. This hormone is also found in fe-
tal blood, though in much smaller amounts
than in maternal blood. The increase in the
secretion of hPL during pregnancy follows
the evolution of the placental mass, and more
particularly, the syncytiotrophoblastic mass,
which is the site of its synthesis. Its real physi-
ological role remains to be elucidated. Indeed,
normal pregnancies have been described in
the absence of hPL secretion. In the last few
years several studies have underlined the im-
portant role of a growth hormone specifically
produced by the placenta, i.e., the placental
growth hormone (review Alsat et al., 1997;
Lacroix et al., 2002). This hormone, a product
of the GH-V gene, is expressed specifically in
the syncytiotrophoblast and differs from the
pituitary growth hormone by 13 amino acids.
It gradually replaces the pituitary growth hor-
mone in maternal circulation and becomes
undetectable during the second trimester of
pregnancy. Secreted continuously by the pla-
centa, it seems to control the synthesis of ma-
ternal IGF-1. Indeed, maternal IGF-1 levels
are in correlation with placental GH levels.
Moreover, in pathology, during pregnancies
of acromegalic women, maternal IGF-1 in-
creases gradually, thus, following the profile
of placental GH, in spite of very high sta-
ble levels of pituitary GH. The secretion of
placental GH, but not of hPL or hCG, is in-
hibited in vitro by glucose in explants and in
trophoblastic cells. In vivo, in the event of ges-
tational diabetes, the levels of placental GH
decrease in maternal blood during an oral glu-
cose tolerance test. This suggests a metabolic
role for placental growth hormone, secreted
specifically in the maternal compartment and
not detected in fetal circulation. In the event
of a fall in maternal glycemia, placental GH,
which is then secreted abundantly by the pla-
centa, will maintain an energetic flux to the
fetus. Recently, we demonstrated that this hor-
mone is also involved in the complex mecha-
nisms, which regulate trophoblastic invasion
into the maternal uterine wall. Indeed, placen-
tal GH, secreted by the invasive trophoblast,
increases trophoblastic invasion by an au-
tocrine/paracrine mechanism (Lacroix et al.,
2005).
The syncytiotrophoblast also secretes other
peptide hormones with maternal levels that
increase gradually throughout pregnancy,
thus, reflecting the progressive increase in the
syncytiotrophoblastic mass. Such is the case
with inhibin A and activin A (Debiève et al.,
2000). These two hormones, members of the
TGFβF super-family, are dimeric hormones,
whose exact role during pregnancy remains to
be elucidated. Only in vitro studies on cultures
of trophoblastic cells underline their modulat-
ing role on trophoblastic hormonal secretion.
Recently, the synthesis of leptin, produced by
fat cells, was also localized in the syncytiotro-
phoblast, and its circulating levels are high
in maternal circulation. Its role during preg-
nancy is unknown. High levels of maternal
circulating leptin are observed, in the event of
maternal diabetes or of pre-eclampsia (see for
review: Sagawa et al., 2002).
STEROID HORMONES
As early as the 6th week of pregnancy, the
human placenta is the site of an important
production of steroid hormones, which are
mainly progesterone and estrogens: estriol,
estradiol and estrone. At term, the daily pla-
cental production of progesterone is about
300 mg (see for reviews: Albrecht and Pepe,
1990; Payne and Hayles, 2004)..
Progesterone essentially acts on the uterus
and is required for myometrium quiescence.
During the first six weeks of pregnancy,
the production of progesterone is primar-
ily carried out by the gravidic ovary cor-
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Figure 2. Scheme of placental steroidogenesis. E1: estrone; E2: estradiol; E3: estriol; P5:
pregnenolone; P4: progesterone; DHA: dehydroepiandrosterone; MLN64: metastatic lymph
node 64.
pus luteum. It is thus associated with a
secretion of 17αhydroxy progesterone, pro-
duced exclusively by the ovary at this stage
of pregnancy. Placental progesterone produc-
tion gradually takes over with the appear-
ance within the syncytiotrophoblast of the
various enzymatic systems necessary for its
synthesis. The precursor to progesterone is
cholesterol. The de novo synthesis of choles-
terol from acetyl CoA is not significant in
the placenta. The maternal origin of placental
cholesterol has been demonstrated; the tro-
phoblast captures cholesterol carried by ma-
ternal plasmatic lipoproteins (Wadsack et al.,
2003). Indeed, second and third trimesters of
pregnancy are characterized by high levels
of maternal circulating total cholesterol, tri-
glycerides, low-density lipoproteins (LDL
cholesterol), and high-density lipoproteins
(HDL cholesterol). The syncytiotrophoblast’s
apical microvillus membrane, in direct con-
tact with maternal blood, presents specific
receptors for these lipoproteins (LDL recep-
tor, VLDL receptor, B1 scavenger receptor). It
has been shown that the syncytiotrophoblast
captures and metabolizes LDL by specific re-
ceptor-mediated endocytosis. Indeed, as early
as the 6th week of pregnancy, LDL recep-
tors are present on the syncytiotrophoblast’s
microvillus membrane. After internalization,
LDL is degraded in the lysosomes to release
cholesterol, which will be used for steroido-
genesis and cellular membrane synthesis. The
direct involvement of LDL receptors in prog-
esterone synthesis is confirmed by the obser-
vation that in vitro estrogens stimulate LDL
receptor expression, inducing an increase in
progesterone synthesis (Albrecht and Pepe,
1990). However, this pathway is not sufficient
to explain the very high placental require-
ment in cholesterol. Recent studies point to
the complementary role of other ways of ac-
complishing cholesterol uptake. For example,
another manner could include the selective
cholesterol uptake pathway, which involves
the scavenger receptor B1 (SR-B1), localized
in syncytiotrophoblastic microvilli. The SR-B1
binds HDL, LDL, and VLDL, as well as mod-
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ified lipoproteins. In this case, the cholesterol
esters are captured by the syncytiotrophoblast
without the internalization and degradation
of apoproteins (Wadsack et al., 2003). Free cho-
lesterol is transported by the Sterol Carrier
Protein-2 (SCP2) to the external membrane of
the mitochondria and then on to the internal
membrane by way of the MLN64 (metastatic
lymph node 64). MLN64 presents a final do-
main similar to the stAR(steroidogenic acute
regulatory protein), a protein expressed in the
other steroidogenic tissues (corpus luteum,
adrenals) (Strauss III et al., 2000; Tuckey et
al., 2001). Within the internal membrane of
the mitochondria, P-450 cytochrome scc (cho-
lesterol side chain cleavage) allows the con-
version of cholesterol into pregnenolone. This
reaction requires electrons provided by mi-
tochondrial adrenodoxin (ADX) and adreno-
doxin reductase (AdRed) activities. Only one
gene (P-450XIA) coding for P-450scc, local-
ized on chromosome 15, is present in the pla-
centa, as early as the 10th week of pregnancy.
Pregnenolone is then converted into proges-
terone by the 3βhydroxysteroid-deshydroge-
nase/isomerase (3βHSD), also localized in the
mitochondria. Several genes, coding for dif-
ferent 3β HSD isoforms, are described. In the
placenta, only the type 1 gene is expressed.
The coordinated action of two transcription
factors determines the specific expression of
the 3βHSD1 in the human placenta (Peng
et al., 2004). Those two transcription factors
are TEF-5 (transcription enhancer Factor V),
which is strongly expressed in the human pla-
centa, and a GATA-like protein.
For estrogen synthesis, in contrast to other
steroidogenic organs, the placenta does not
express cytochrome P450 17α - hydroxylase/
17:20 lyase and, therefore, cannot convert
pregnenolone and progesterone into andro-
gens. Thus, the production of placental es-
trogens is the tributary of a precursor an-
drogen, sulphate of dehydroepiandrosterone
(S-DHA), produced by the maternal and fe-
tal adrenal glands. Estrogen synthesis, orig-
inating from the fetal adrenal glands, in-
creases progressively during pregnancy. At
term, fetal adrenal glands are involved in 40%
of the production of estrone and estradiol
and in 90% of the production of estriol. S-
DHA diffuses from fetal blood to the syncy-
tiotrophoblast and is hydrolyzed by a sterol
steroid sulfatase; DHA is then metabolized
in androstendione by a 3β HSD. Androsten-
dione is transformed into testosterone by a 17
β-hydroxysteroid dehydrogenase (17 βHSD),
encoded by the HSD17B1 gene, localized
on chromosome 17 (17q11-q21). C19 andros-
terone and testosterone are then aromatized in
C18 estrogens (estrone and estradiol, respec-
tively) by the P450 cytochrome aromatase,
encoded by the CYP19 gene, only present in
the syncytiotrophoblast. Fetal adrenal S-DHA
can also undergo 16α-hydroxylation in the
fetal liver, leading to the formation of 16α-
hydroxy S-DHA, the precursor to estriol an-
drogen. Thus, 90% of placental estriol arises
from the activities of the fetal adrenal glands
and the liver. This cooperation between the
placenta and the fetus has led to the concept
of a feto-placental unit (see figure 2).
If numerous factors, such as hCG, cAMP,
and prostaglandins, have been described to
modulate in vitro placental estrogen synthesis,
the quality of the fetal adrenal glands’ devel-
opment remains the essential factor.
If progesterone is absolutely required for
the well being of pregnancy, the role of es-
trogens still remains uncertain. Estrogens in-
duce progesterone receptors’ synthesis in the
myometrium and stimulate the incorpora-
tion of lipoproteins and CYP11A1 expression,
therefore, modulating progesterone synthesis.
In addition, in vitro E2 stimulates the for-
mation of the syncytiotrophoblast (Malassiné
and Cronier, 2002). However, as will be de-
tailed further, genetic deficiencies in placental
sulfatase or aromatase, leading to very low
levels of maternal circulating estrogens, are
associated with normal pregnancy.
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OTHER FACTORS
In the last few years, the production of
neuropeptides has been highlighted in the
placenta, an organ deprived of innervation.
These neuropeptides are similar to those
found in the hypothalamo-pituitary system
or in the digestive tract (TRH, GnRH, CRH,
somatostatin, grhelin...). In trophoblastic cul-
tured cells in vitro, they modulate the pla-
cental hormonal secretion by autocrine or
paracrine mechanisms (Petraglia et al., 1996).
It must be pointed out that, during pregnancy,
the placenta and the fetal membranes produce
large amounts of CRH (Corticotropin Releas-
ing Hormone). Placental CRH progressively
increases during pregnancy, due to an in-
crease in its gene expression. It was thus pro-
posed that CRH, interacting with estrogens,
fetal adrenal steroids and prostaglandins, es-
tablishes a stimulative autocrine loop, which
could initiate parturition (Mc Lean and Smif,
2001). Lastly, the placenta is the site of ex-
pression of many growth factors implicated in
its development, such as IGFs and cytokines
(Fowden, 2003). Some placental factors im-
plied in angiogenesis could be early markers
for pre-eclampsia. Thus, an increase in the
levels of the soluble VEGF receptor (vascular
endothelial growth Factor) and a reduction in
the levels of PLGF (placental growth Factor)
are observed in maternal circulation during
the first trimester of pregnancy, before any
of the clinical signs of pre-eclampsia have pre-
sented ( Lewine et al., 2004; Tadani et al., 2004).
HORMONAL PATHOLOGIES
OF PREGNANCY
The peak of hCG in maternal circulation
is associated with a decrease in maternal
TSH levels. Indeed, hCG binds to TSH recep-
tors and stimulates thyroid cells. This thyreo-
stimulating effect of hCG can lead to the
appearance of a maternal goiter, observed
more frequently in twin pregnancies, where
hCG levels are higher. Recently, several stud-
ies stress the importance of the glycosylation
state of hCG, which varies according to the
stage of the pregnancy. The glycosylation of
hCG is modified in choriocarcinomas and in
feto-placental trisomy 21. The increased lev-
els of hCG observed in maternal circulation,
in the case of feto-placental trisomy 21, are
used in clinical practice as a maternal serum
marker in prenatal screening. It was recently
demonstrated that this hCG increase is related
to an abnormal glycosylation of this hormone,
modifying its biological activity and its clear-
ance in the materno-placental compartment
(Frendo et al., 2004). It is now well established
that the levels of placental GH and IGF-1 are
lowered in cases of intra-uterine growth re-
tardation (Mirlesse et al., 1993). The placental
sterol sulfatase deficit leads to a very impor-
tant reduction in the secretion of the estro-
gens. This enzymatic deficit is linked to the X
chromosome, affecting the male fetus and is
associated with ichthyosis (Bedin et al., 1987).
Another genetic abnormality, associated with
very low levels of maternal estrogens, is the
deficit in CYP19 (P450 aromatase). In this case,
maternal and fetal virilisation is observed,
due to the weak aromatization of androgens
(Shozu et al., 1991). Finally, the family deficit
of β lipoproteins is one of the rare condi-
tions of abnormal placental steroidogenesis
and is related to an insufficient uptake of
cholesterol in the syncytiotrophoblast. Appar-
ently, it is associated with normal pregnancies.
The specificity of human placental steroido-
genesis was recently illustrated by the fact
that the protein implied in the translocation
of cholesterol to the internal mitochondrial
membrane (STAR) was not expressed in the
trophoblast, but rather, in the fetal adrenals
(Tuckey et al., 2004). Thus, a null mutation of
this gene, which is associated with a poten-
tially lethal fetal adrenal lipoid hyperplasia,
does not modify the normal course of preg-
nancy. However, the absence of testosterone
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production by Leydig cells is associated with
a female phenotype at birth (Hasegawa et al.,
2000).
In addition, maternal or fetal cortisol can
be deactivated by the placenta into cortisone.
This regulates the quantity of active gluco-
corticoids available to the fetus. The syn-
cytiotrophoblast expresses the 11β-hydroxys-
teroid deshydrogenase (type 2) throughout
pregnancy. Any defect in syncytiotrophoblas-
tic development or function decreases this
enzyme, therefore, inducing a fetal hypercor-
tisolism (Seckle et al., 2000).Furthermore, an
intra-uterine growth retardation is associated
with a null mutation or a reduction in the
expression of the 11β-hydroxysteroid deshy-
drogenase (Dave-Sharma et al., 1998). This tro-
phoblastic enzymatic activity has therapeu-
tic implications. In the prenatal treatment of
21α hydroxylase deficiency in a female fetus,
the maternal treatment must be unmetabo-
lized dexamethasone, instead of hydrocorti-
sone, which is transformed into cortisone by
the trophoblast.
CONCLUSION
This article is dedicated to José Sáez who
trained Danièle Evain-Brion in Endocrinology
and allowed her to discover the fascinating
interaction between clinical and fundamental
research. José Sáez was an exceptional master
and a great scientist with whom it was always
a great pleasure to discuss any research topic.
José Sáez was a friend.
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